Testing experimental cancer drugs in mouse models with patient-derived tumors could reduce the high failure rate of drugs in early clinical trials, according to a new report.
Testing experimental cancer drugs in mouse models with patient-derived tumors could reduce the high failure rate of drugs in early clinical trials, according to a new report.